Biomea Fusion is a biopharmaceutical company focused on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. It develops an inhibitor of menin that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes, including cell cycle control, apoptosis, and DNA damage repair.